Schisandrin B from Schisandra chinensis reduces hepatic lipid contents in hypercholesterolaemic mice

Journal of Pharmacy and Pharmacology

Volumn 60, Issue 3, 2008, Pages 399-403

  Pan, Si Yuan ^a   Dong, Hang ^a   Zhao, Xing Ye ^a   Xiang, Chun Jing ^a   Fang, Hai Yan ^a   Fong, Wang Fun ^b   Yu, Zhi Ling ^b   Ko, Kam Ming ^c  

^a BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

^c HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

BILE SALT; CHOLESTEROL; FENOFIBRATE; SCHIZANDRIN B; TRIACYLGLYCEROL;

ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; DRUG EFFECT; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; LIPID DIET; MALE; MOUSE; NONHUMAN; SCHISANDRACEAE;

ANIMALS; ANTILIPEMIC AGENTS; BILE ACIDS AND SALTS; CHOLESTEROL; CHOLESTEROL, DIETARY; CYCLOOCTANES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY LIVER; HYPERCHOLESTEROLEMIA; LIGNANS; LIVER; MALE; MICE; MICE, INBRED ICR; POLYCYCLIC COMPOUNDS; PROCETOFEN; SCHISANDRA; TRIGLYCERIDES;

EID: 39449088904     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.60.3.0017     Document Type: Article

References (26)

1. Akyol, G., Erdem, O., Yilmaz, G. (2005) Nonalcoholic fatty liver disease. Correlation with histology and viral hepatitis. Saudi Med. J. 26: 1904-1910
2. Andersson, Y., Majd, Z., Lefebvre, A. M., Martin, G., Sechkin, A. V., Kosykh, V., Fruchart, J. C, Najib, J., Staels, B. (1999) Developmental and pharmacological regulation of apolipoprotein C-II gene expression. Comparison with apo C-I and apo C-III gene regulation. Arterioscler. Thromb. Vasc. Biol. 19: 115-121
3. Chiu, P. Y., Tang, M. H., Mak, D. H., Poon, M. K., Ko, K. M. (2003) Hepatoprotective mechanism of schisandrin B: role of mitochondrial glutathione antioxidant status and heat shock proteins. Free Radic. Biol. Med. 35: 368-380
4. Comar, K. M., Sterling, R. K. (2006) Review article: Drag therapy for non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 23: 207-215
5. Deng, X. G., Chen, L. L., Li, N. X. (2007) The expression of SIRT1 in nonalcoholic fatty liver disease induced by high-fat diet in rats. Liver Int. 27: 708-715
6. Fan, J. G., Zhu, J., Li, X. J., Chen, L., Lu, Y. S., Li, L., Dai, F., Li, F., Chen, S. Y. (2005) Fatty liver and the metabolic syndrome among Shanghai adults. J. Gastroenterol. Hepatol. 12: 1825-1832
7. Farrell, G. C., Latter, C. Z. (2006) Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43(S1): 99-112
8. Festi, D., Colecchia, A., Sacco, T., Bondi, M., Roda, E., Marchesini, G. (2004) Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obes. Rev. 5: 27-42
9. Frederiksen, K. S., Wulf, E. M., Wassermann, K., Sauerberg, P., Fleckner, J. (2003) Identification of hepatic transcriptional changes in insulin-resistant rats treated with peroxisome proliferator activated receptor-alpha agonists. J. Mol. Endocrinol. 30: 317-329
10. Grieco, A., Forgione, A., Miele, L., Vero, V., Greco, A. V., Gasbarrini, A., Gasbarrini, G. (2005) Fatty liver and drags. Eur. Rev. Med. Pharmacol. Sci. 9: 261-263
11. Ip, S. P., Wu, S. S., Poon, M. K. T., Che, C. T., Ng, K. H., Kong, Y. C. Ko, K. M. (1995) Effect of schisandrin B on hepatic glutathione antioxidant system in mice: protection against carbon tetrachloride toxicity. Planta Med. 61: 398-401
12. Ip, S. P., Che, C. T., Kong, Y. C., Ko, K. M. (2001) Effects of schisandrin B pretreatment on tumor necrosis factor-alpha induced apoptosis and Hsp70 expression in mouse liver. Cell Stress Chaperones 6: 44-48
13. Jian, W. Y., Shu, C. L., Gui, Q. W. (2006) Effects of fatty liver and related factors on the efficacy of combination antiviral therapy in patients with chronic hepatitis C. Liver Int. 26: 166-172
14. Ko, R. K. M., Mak, D. H. F. (2004) Schisandrin B and other dibenzocyclooctadiene lignans. In: Packer, L., Halliwell, B., Ong, C. N. (eds) Modern herbal medicine: molecular basis in health & disease management. Marcel Dekker, New York, Basel, Hong Kong, pp 289-314
15. Mager, D. R., Roberts, E. A. (2006) Nonalcoholic fatty liver disease in children. Clin. Liver Dis. 10: 109-131
16. McKenney, J. M., Farnier, M., Lo, K. W., Bavs, H. E., Perevozkava, I., Carlson, G., Davies, M. J., Mitchel, Y. B., Gumibiner, B. (2006) Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J. Am. Coll. Cardiol. 47: 1584-1587
17. Miura, Y., Hosono, M., Oyamada, C., Odai, H., Oikawa, S., Kondo, K. (2005) Dietary isohumulones, the bitter components of beer, raise plasma HDL-cholesterol levels and reduce liver cholesterol and triacylglycerol contents similar to PPARalpha activations in C57BL/6 mice. Br. J. Nutr. 93: 559-567
18. Mounie, J., Champion, L., Goudonnet, H., Escousse, A., Trchot, R. C. (1988) Inductive effects of fenofibrate and metabolism of phenobarbital. Fundam. Clin. Pharmacol. 2: 259-265
19. Packard, C. J. (1998) Overview of fenofibrate. Eur. Heart. J. 19 (Suppl. A): 62-65
20. Pan, S. Y., Dong, H., Han, Y. F., Li, W. Y., Zhao, X. Y., Ko, K. M. (2006a) A novel experimental model of acute hypertriglyceridemia induced by schisandrin B. Eur. J. Pharmacol. 537: 200-204
21. Pan, S. Y., Yang, R., Han, Y. F., Dong, H., Feng, X. D., Li, N., Wei, G., Ko, K. M. (2006b) High doses of bifendate elevate serum and hepatic triglyceride levels in rabbits and mice: animal models of acute hypertriglyceridemia. Acta Pharmacol. Sin. 27: 673-678
22. Pan, S. Y., Yang, R., Dong, H., Yu, Z. L., Ko, K. M. (2006c) Bifendate treatment attenuates hepatic steatosis in cholesterol/bile salt- and high-fat diet-induced hypercholesterolemia in mice. Eur. J. Pharmacol. 552: 170-175
23. Sanval, A. I. (2005) Mechanisms of disease: pathogenesis of nonalcoholic fatty liver disease. Nat. Clin. Pract Gastroenterol. Hepatol. 2: 46-53
24. Tilg, H., Kaser, A. (2005) Treatment strategies in nonalcoholic fatty liver disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 2: 148-155
25. Tsimihodimos, V., Miltiadous, G., Daskalopoulou, S. S., Mikhailidis, D. P., Elisaf, M. S. (2005) Fenofibrate: metabolic and pleiotropic effects. Curr. Vasc. Pharmacol. 3: 87-98
26. Zhang, Y., Xie, M., Xue, J., Gu, Z. (2007) Osthole improves fat milk-induced fatty liver in rats: modulation of hepatic PPAR-alpha/gamma- mediated lipogenic gene expression. Planta Med. 73: 718-724